🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsTirzepatide (Mounjaro / Zepbound)Mounjaro savings card update — July 2024 Page 5

Mounjaro savings card update — July 2024

tammy_FL Wed, Feb 7, 2024 at 5:59 PM 60 replies 3,510 viewsPage 5 of 12
Dr.PainCLE
Senior Member
1,234
6,234
Mar 2024
Cleveland, OH
Feb 9, 2024 at 8:15 AM#21

From the other side of the consultation, briefly. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.

Ask again with the specifics and you will get a better answer than this one.

31 4Dr.PathRoch, mona_PHX, andrew_nyc and 28 others
Reply Quote Save Share Report
DoseLogDan
Member
201
567
Feb 2025
Montana
Feb 9, 2024 at 2:40 PM#22
Dr.PainCLE said:
Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the…

Mine went the same way, slower.

Last edited: Feb 9, 2024 at 3:40 PM
32 5Dr.AddMedPHL, newstart_MO, mia_MS2 and 29 others
Reply Quote Save Share Report
GenomicsKate
Member
345
1,890
Oct 2024
Cambridge, MA
Feb 9, 2024 at 9:05 PM#23
Dr.PainCLE said:
Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the…

Adding the part of the answer the thread has not reached. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

33 6MarkLI_maint, Dr.PeteFamMed, claudia_zurich and 30 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
lisa_labSD
Member
278
1,234
Oct 2024
San Diego, CA
Feb 10, 2024 at 3:30 AM#24

One concrete data point for the thread. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

Last edited: Feb 10, 2024 at 6:30 AM
34 7lori_vegas, Dr.PulmRoch, maya_sedona and 31 others
Reply Quote Save Share Report
jason_sac26
New Member
34
123
Jan 2026
Sacramento, CA
Feb 10, 2024 at 9:55 AM#25

Following on from Dr.PainCLE — and this may be the naive question:

Was that from a primary source or from a summary of one?

35 8Dr.PulmRoch, maya_sedona, stefan_berlin and 32 others
Reply Quote Save Share Report
13456712

Similar Threads

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — full results11 replies
SURPASS 1-5 program: tirzepatide T2DM efficacy data compilation6 replies
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism18 replies
5mg → 10mg → 15mg titration — clinical guidance and real-world data8 replies
Zepbound insurance coverage — payer-by-payer breakdown 20268 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register